Inno-206
Adult Mixed Glioma
Washington University School of MedicinePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the Adult Mixed Glioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cediranib National Cancer Institute (NCI) | Phase 2 | BBB |
Irinotecan National Cancer Institute (NCI) | Phase 1/2 | B |
(+)-VINCRISTINE Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1/2 | B |
Temsirolimus Andrew B Lassman, MD | Phase 1/2 | B |
ETOPOSIDE Washington University School of Medicine | Phase 2 | B |
View all 29 →
Same molecule, other indications
Inno-206 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →